Journal article
Mobile health intervention to increase oral cancer therapy adherence in patients with chronic myeloid leukemia (The REMIND system): Clinical feasibility and acceptability assessment
A Pereira-Salgado, JA Westwood, L Russell, A Ugalde, B Ortlepp, JF Seymour, P Butow, L Cavedon, K Ong, S Aranda, S Breen, S Kirsa, A Dunlevie, P Schofield
Jmir Mhealth and Uhealth | JMIR PUBLICATIONS, INC | Published : 2017
DOI: 10.2196/mhealth.8349
Abstract
Background: Optimal dosing of oral tyrosine kinase inhibitor therapy is critical to treatment success and survival of patients with chronic myeloid leukemia (CML). Drug intolerance secondary to toxicities and nonadherence are significant factors in treatment failure. Objective: The objective of this study was to develop and pilot-test the clinical feasibility and acceptability of a mobile health system (REMIND) to increase oral drug adherence and patient symptom self-management among people with CML (chronic phase). Methods: A multifaceted intervention was iteratively developed using the intervention development framework by Schofield and Chambers, consisting of defining the patient problem ..
View full abstractRelated Projects (1)
Grants
Awarded by Seventh Framework Programme
Funding Acknowledgements
This study was supported by a Peter MacCallum Cancer Foundation Grant and a seed funding grant from Australasian Leukaemia and Lymphoma Group. PS was supported by a National Health and Medical Research Council Career Development Award, ID 628563. JS has received honoraria as a member of the Novartis Advisory Board. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study has received institutional approval by the Peter MacCallum Ethics Committee, Ethics #E22-10. The authors would like to thank the patients who participated and Dhirendra Singh, Catherine Vassili, and Andrew Murnane for their assistance in the study.